Vaccine ConfidenceVACCINE-WESTNCT07878442
Tailored Vaccine Messaging for Parents/Caregivers of Adolescents
A study testing Tailored Vaccine Messaging and Standard Vaccine Message in people with Vaccine Confidence and Adolescent Vaccination, run by University of Utah at 1 site in United States.
Trial summary
his study will evaluate whether tailored vaccine messaging improves vaccination-related outcomes among parents and caregivers of adolescents. Participants will complete a baseline electronic survey and will then be randomly assigned to receive either a tailored vaccine message based on insurance status or a standard… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Vaccine Confidence, Adolescent Vaccination, Vaccine Uptake
- What is being tested?
- Tailored Vaccine Messaging and Standard Vaccine Message
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,000 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2026to Apr 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 18 and older
- Parents/caregivers (P/C) of children/teens (C/A) aged 9 to <18 years old, including those with public insurance/uninsured or private insurance
- Young adults (YAs) aged 18-26 residing in states west of the Mississippi River
Who cannot join
- Anyone not meeting the inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Kaila Christini, MS, MsPH, 801-581-6419, Kaila.Christini@hci.utah.edu
Deanna Kepka, PhD, MPH
About this study
Official title: Assessment of Adolescent and Young Adult Vaccine Confidence and Missed Opportunities for Vaccination in the Mountain West (VACCINE CONFIDENCE - WEST): A Randomized Tailored Vaccine Messaging Intervention
his study will evaluate whether tailored vaccine messaging improves vaccination-related outcomes among parents and caregivers of adolescents. Participants will complete a baseline electronic survey and will then be randomly assigned to receive either a tailored vaccine message based on insurance status or a standard vaccine message delivered by SMS text message. Approximately four weeks after receiving the intervention message, participants will complete a follow-up electronic survey assessing vaccination behaviors, vaccination intentions, vaccine confidence, perceived barriers to adolescent vaccination, and perceptions of the intervention message.
Read the detailed description
This randomized intervention study will evaluate the effectiveness of tailored vaccine messaging among parents and caregivers of adolescents. Participants will complete a baseline electronic survey assessing sociodemographic and geographic characteristics, vaccination behaviors, vaccine confidence, vaccine hesitancy, perceived barriers to vaccination, vaccine knowledge, and related vaccine perceptions.
Following completion of the baseline survey, participants will be randomized in a 1:1 ratio to receive either tailored vaccine messaging based on insurance status (public insurance/uninsured versus private insurance) or a standard vaccine message. Intervention messages will be delivered via SMS text messaging.
Approximately four weeks after intervention delivery, participants will complete a follow-up electronic survey assessing vaccination behaviors, vaccination intentions, vaccine confidence, perceived barriers to adolescent vaccination, and perceptions of the intervention message.
The study will also collect available intervention process measures, which may include successful message delivery, message receipt and/or opening when available, timing of message delivery, elapsed time between intervention delivery and follow-up survey completion, and other available messaging metadata. These measures will be used to characterize intervention implementation and participant engagement and to inform future messaging interventions.
- Conditions
- Vaccine Confidence, Adolescent Vaccination, Vaccine Uptake
- Being tested
- Tailored Vaccine Messaging, Standard Vaccine Message
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tailored Vaccine MessagingBehavioural
SMS text message providing vaccine-related information and messaging tailored according to participant insurance status.
Participants are randomized 1:1 to this intervention group following completion of the baseline survey.
Standard Vaccine MessageBehavioural
SMS text message providing standardized vaccine-related information and messaging without tailoring based on insurance status.
Intervention Assignment: Participants are randomized 1:1 to this comparison group following completion of the baseline survey.
| Study group | Role | What they receive |
|---|---|---|
| Tailored Messaging Group | Experimental | Participants will receive a vaccine message tailored according to insurance status (public insurance/uninsured versus private insurance) following completion of the baseline survey. Receives: Behavioral: Tailored Vaccine Messaging |
| Standard Messaging Group | Active comparator | Participants will receive a standard vaccine message following completion of the baseline survey. Receives: Behavioral: Standard Vaccine Message |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in vaccination intentions
Change in participant-reported intention to obtain recommended adolescent vaccinations from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
Measured: Baseline to approximately 4 weeks after intervention message delivery.
Change in vaccine confidence
Change in participant-reported vaccine confidence from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
Measured: Baseline to approximately 4 weeks after intervention message delivery.
Secondary outcomes (1)
Self-reported vaccination behavior
Change in participant-reported adolescent vaccination behavior from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
Measured: Baseline to approximately 4 weeks after intervention message delivery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study startOct 2026 (estimated)
- Primary completionFeb 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vaccine ConfidenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will complete a baseline electronic survey and then be randomized 1:1 to receive either tailored vaccine messaging based on insurance status or a standard vaccine message.
- Masking
- None (open label)
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- Merck & Co., Inc.; Huntsman Cancer Institute's Intermountain West HPV Vaccination Coalition.
- Responsible party
- Sponsor
- Investigators
- Deanna Kepka, PhD, MPH, Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07878442
- Sponsor's protocol ID
- 206720
- Other IDs
- 10066664
- Acronym
- VACCINE-WEST
- Status last verified
- Oct 2026
- First submitted
- 9 Oct 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No